Tri-modality strategy with Docetaxel plus five-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced esophageal cancer

Phase 2

• Conditions: Esophageal cancer

• Registration Number: JPRN-UMIN000011089
• Lead Sponsor: Shizuoka Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Not provided

Exclusion Criteria

1) Simultaneous or metachronous (within 5 years) double cancers, except for intramucosal tumor curatively resected by local therapy 2) Active infection requiring systemic therapy 3) Positive HBs antigen, HCV antibody or HIV antibody 4) Pregnant or lactating women or women of childbearing potential 5) Psychiatric disease 6) Patients requiring systemic steroids medication 7) Hypersensitivity for docetaxel, cisplatin or polysorbate 80 containing drug 8) Uncontrolled diabetes mellitus 9) Severe emphysema or pulmonary fibrosis 10) Unstable angina within 3 weeks, or with a history of myocardial infarction within 3 months. 11) Any other cases who are regarded as inadequate for study enrollment by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified